Aptevo Therapeutics Inc. (APVO)

Market Cap	15.32M
Revenue (ttm)	9.88M
Net Income (ttm)	7.04M
Shares Out	5.09M
EPS (ttm)	1.15
PE Ratio	2.62
Forward PE	3.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,897
Open	3.06
Previous Close	3.12
Day's Range	3.00 - 3.33
52-Week Range	3.00 - 22.08
Beta	5.82
Analysts	Buy
Price Target	18.36 (+510.0%)
Earnings Date	Aug 11, 2022

About APVO

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a ...

• Industry: Biotechnology
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: APVO

Full Company Profile

Financial Performance

In 2021, APVO's revenue was $12.29 million, an increase of 185.26% compared to the previous year's $4.31 million. Losses were -$28.46 million, 60.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for APVO stock is "Buy." The 12-month stock price forecast is 18.36, which is an increase of 509.97% from the latest price.

Price Target

$18.36

(509.97% upside)

Analyst Consensus: Buy

Stock Forecasts